BioMarin Pharmaceutical clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   PALLADIUM · Rapid Drug Desensitization Study in Adults…PALLADIUM · Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq

   Trial completed

   BioMarin Pharmaceutical·Phase 4· NCT06780332· Registry history of NCT06780332 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

2. Minor

   Vosoritide · Noonan Syndrome With Inadequate Growth During or…Vosoritide · Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

   Enrollment closed, study ongoing

   Also in this update: Trial sites reduced: 41 → 38 locations

   BioMarin Pharmaceutical·Phase 2· NCT06668805· Registry history of NCT06668805 on ClinicalTrials.gov (opens the registry)

   Sep 23, 2026

3. Minor

   ASPEN · BMN 333 Versus Vosoritide · Achondroplasia

   Trial sites expanded: 25 → 28 locations

   BioMarin Pharmaceutical·Phase 2/3· NCT07441876· Registry history of NCT07441876 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.